517 related articles for article (PubMed ID: 11368288)
21. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
22. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
23. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
24. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
[TBL] [Abstract][Full Text] [Related]
25. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
26. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
[TBL] [Abstract][Full Text] [Related]
27. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
28. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
29. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
31. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
Castiglione F; Dalla Mola A; Porcile G
Tumori; 1999; 85(2):85-91. PubMed ID: 10363072
[TBL] [Abstract][Full Text] [Related]
32. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
33. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
34. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
35. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
37. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
38. Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases--a clinical study including the pharmacoeconomic analysis.
Stolarska M; Mlynarski W; Zalewska-Szewczyk B; Bodalski J
Pharmacol Rep; 2006; 58(1):30-4. PubMed ID: 16531627
[TBL] [Abstract][Full Text] [Related]
39. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
